Systematic Review and Meta-analysis

The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease

(2016) N. Narula et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease

(2016) J. Cosnes et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study

(2016) J. D. Doecke et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

(2016) B. Ungar et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab

(2016) Mark T Osterman et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Adalimumab in Korean Patients with Crohn's Disease

(2016) Il Woong Sohn et al.   Gut and Liver

A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease

(2016) P. Varma et al.   INTERNAL MEDICINE JOURNAL

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial

(2016) Takayuki Matsumoto et al.   Journal of Crohns & Colitis

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease

(2016) Haruhiko Ogata et al.   Journal of Crohns & Colitis

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

(2016) Fernando Gomollón et al.   Journal of Crohns & Colitis

Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

(2016) Remo Panaccione et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

(2015) Sarah S. Thomas et al.   BIODRUGS

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials

(2015) Jennifer L. Jones et al.   Clinical Gastroenterology and Hepatology

Addition of an Immunomodulator as a Rescue Therapy for Loss of Response to Adalimumab Dose Escalation in Patients With Crohn’s Disease: Figure 1.

(2015) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Influence of Combination Therapy with Immune Modulators on Anti-TNF Trough Levels and Antibodies in Patients with IBD

(2014) Tamara van Schaik et al.   INFLAMMATORY BOWEL DISEASES

Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD

(2014) Madeline Therese Frederiksen et al.   INFLAMMATORY BOWEL DISEASES

Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease

(2014) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis

(2014) Uri Kopylov et al.   Journal of Crohns & Colitis

Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients

(2014) Charlotte P. Peters et al.   Journal of Crohns & Colitis

Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents

(2013) Christine Kestens et al.   Clinical Gastroenterology and Hepatology

American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease

(2013) Themistocles Dassopoulos et al.   GASTROENTEROLOGY

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

(2013) Mark T. Osterman et al.   GASTROENTEROLOGY

P493 Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD

(2013) P. Noertersheuser et al.   Journal of Crohns & Colitis

Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients

(2013) Kumi Ishida   WORLD JOURNAL OF GASTROENTEROLOGY

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

(2012) C. Reenaers et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience

(2011) José Ignacio Fortea-Ormaechea et al.   Gastroenterologia y Hepatologia

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE

(2011) Robert Löfberg et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience

(2011) Michael B. Sprakes et al.   Journal of Crohns & Colitis

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

(2010) H. Sokol et al.   GUT

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

(2008) Brian G. Feagan et al.   GASTROENTEROLOGY